WO2003030918A1 - Produit pharmaceutique ou complement alimentaire, et produit intermediaire a utiliser avec ces produits - Google Patents

Produit pharmaceutique ou complement alimentaire, et produit intermediaire a utiliser avec ces produits Download PDF

Info

Publication number
WO2003030918A1
WO2003030918A1 PCT/NL2002/000640 NL0200640W WO03030918A1 WO 2003030918 A1 WO2003030918 A1 WO 2003030918A1 NL 0200640 W NL0200640 W NL 0200640W WO 03030918 A1 WO03030918 A1 WO 03030918A1
Authority
WO
WIPO (PCT)
Prior art keywords
food supplement
product
pharmaceutical product
amount
preparation
Prior art date
Application number
PCT/NL2002/000640
Other languages
English (en)
Inventor
Jeroen Johannes Maria Van Den Berg
Robert Johan Joseph Hageman
Eric Alexander Franciscus Van Tol
Adrianus Johannes Maria Vriesema
Original Assignee
Nutricia N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia N.V. filed Critical Nutricia N.V.
Publication of WO2003030918A1 publication Critical patent/WO2003030918A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A23K10/24—Animal feeding-stuffs from material of animal origin from blood
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to a pharmaceutical product or food supplement which contains a preparation from blood plasma as the active component.
  • the invention further relates to the pharmaceutical product in a form which is suitable for medical use and to the food supplement in solid or liquid form, as well as to an intermediate product to be used.
  • Food supplements containing substances from animal plasma as the active component are known from US patent No 6,004,576. Said food supplements are used for effecting a weight increase in animals and for stimulating their growth.
  • the invention in particular relates to a pharmaceutical product and food supplement containing a specific fraction which can be separated from animal blood.
  • the preparation thus obtained can be administered enterally or topically; in particular, it can be successfully administered to patients who suffer from diarrhoea, from various wounds or infections or from a specific deficiency of the immune system.
  • the pharmaceutical product or food supplement comprises a preparation which contains a larger amount of complement system (CS) and/or antibodies (im unoglobulins) than is normally present as the active component.
  • the preparation in particular contains a larger amount of complement system (CS) than is normally present.
  • CS complement system
  • larger amount of complement system than is normally present is understood to mean an amount such as the amount present in the blood preparations that are (commercially) known so far.
  • the blood plasma of particular animals contains a particular amount of complement system or antibodies. This amount depends in the first place on the animal species in question, for example pigs, cattle, horses or poultry. Furthermore, the amount will vary within a specific species.
  • the blood plasma thus obtained contains a larger amount of complement system (CS) and/or antibodies (immunoglobulins) than is normally present.
  • CS complement system
  • CS complement system
  • said blood plasma contains a higher amount of antibodies (immunoglobulins) than normally present, as well as a number of proteins which together form the complement system (CS) .
  • the preparation contains a complement system and/or antibodies which have not been denatured.
  • an intermediate product from blood plasma containing more than 2.6 g of CS, in particular more than 3.25 g of CS, or more than 4 g of CS per 100 g of (intermediate) product forms the basis for the preparation of the pharmaceutical product or food supplement.
  • the immunoglobulins may be of the so-called 6-type
  • the immunoglobulins may be specific against toxins such as the anti-LT-IgG (heat-unstable toxin) and immunoglobulins which are specific with regard to cholera toxin or the toxins that are developed from or by E-coli or other pathogens. Said antibodies with regard to toxins can be found in normal blood, viz. blood from non- hyperimmune animals.
  • toxins such as the anti-LT-IgG (heat-unstable toxin) and immunoglobulins which are specific with regard to cholera toxin or the toxins that are developed from or by E-coli or other pathogens.
  • Said antibodies with regard to toxins can be found in normal blood, viz. blood from non- hyperimmune animals.
  • the immunoglobulins may also be specific against a larger number of pathogens, such as Helicobacter pylori, Pseudomonas aeruginosis, staphylococcus aureus, E. coli, Salmonella and other Gram- negative or Gram-positive micro-organisms, as well as fungi such as Candida.
  • Titres in the blood of normal (non- hyperimmunised) animals are too low to be active after being administered to humans, so that the animal must be subjected to a hyperimmunisation treatment, using methods which are known per se in this field. It is preferred to use the method that will be explained in more detail hereinafter, in particular if the animal is subjected to a hyperimmunisation treatment with a cocktail of relevant micro-organisms.
  • the active component of the blood also contains proteins, indicated as the "complement system”, or the relevant components thereof.
  • the complement system is a group of glycoproteins which are capable of interaction under specific conditions, which will lead to an enhanced immune response.
  • CS is in particular involved in the activation of immune cells, such as neutrophilic granulocytes and monocytes.
  • CS occurs in the blood of many animals, although the type and the concentration of the various components of CS vary in dependence on the specific species.
  • CS contains proteins which are involved in the activation of the C3-protein, such as the immune complexes Cl, C4 and C2 and the factor B, P and D, which comprise products of bacterial origin.
  • CS also comprises enhanced proteins involved in cytolysis, such as C5-C9 proteins and bioactive fragments or complexes thereof, in particular C5a and C5i67.
  • CS comprises proteins which are involved in the regulation (including the inhibition) of CS, such as Cl-inhibitors, C4 binding protein factor H, I, CD59 (protectin), anafylatoxin-inactivator and S-protein. Under non-inflammatory conditions, the system is in the non-activated form.
  • CS can act in the desired manner when administered to the patient.
  • the essential components must be present in sufficient amounts, which can be determined by the doctor in attendance by carrying out suitable measurements, for example by carrying out a complement-lysis determination. A high degree of synergy can be measured.
  • Essential substances are C3-protein, which makes up more than 30 wt.% of the complement system, and the C5-C9 proteins (C5, C6, C7, C8, C9), which together make up more than five wt.% of CS.
  • the weight ratio of the components of the complement system to the amount of globulins in the product must range between 1:5 and 1:20, in particular between 1:7 and 1:16.
  • the ratio of the amount of components of the complement system without inhibitors of CS to the amount of immunoglobulins ranges between 1:8 and 1:25, in particular between 1:10 and 1:20.
  • the blood component also contains growth factors, such as insulin-like growth factor (IGF), transforming growth factor (TGF), in particular TGF- beta combined with "Latency Associated Protein (LAP)", platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and keratinocyte growth factor (KGF) .
  • IGF insulin-like growth factor
  • TGF transforming growth factor
  • LAP Layer Associated Protein
  • PDGF platelet-derived growth factor
  • EGF epidermal growth factor
  • KGF keratinocyte growth factor
  • the blood product preferably does not contain any fibrinogen (serum) or other components that interfere with the preparation of liquid products from the compotent. Furthermore, the blood product should not contain any impurities such as micro-organisms (pathogens, viruses) or prions.
  • the blood product or the preparation is prepared by carrying out methods of such a nature that the active components are not affected.
  • Both immunoglobulins and in particular the complement system are heat sensitive. Consequently, conventional treatments, which may be used for the isolation and in particular for the concentration of proteins, lead to significant immunoglobulin losses, viz. 20-50% and even more for the components of the complement system.
  • For use in foodstuffs for human beings it is desirable to carr out an additional purification and concentration step by removing, for example, albumins.
  • heat treatments that have been conventionally used so far, such as pasteurisation, vaporisation or sterilisation.
  • the drying of the liquid blood product can also take place directly after the filtration step, but it is preferably carried out on the concentrated material (in which said concentration takes place through dialysis), the standardisation step can take place after said dialysis with regard to the adjustment of the pH value and the adjustment of the salt concentration for the stabilisation and standardisation of the product.
  • Suitable drying techniques are freeze-drying or spray-drying, using specific drying conditions, or a combination thereof.
  • a suitable spray-drying technique is described in Dutch patent No 1016981.
  • the organoleptic properties of the final product are appreciated by the consumer or the patient.
  • specific amounts of the components are present in the product according to the invention.
  • liquid plasma remains, with more than 60%, in particular more than 70%, especially about 80% of the dry material being protein. Only about 20% are immunoglobulins.
  • the removal of albumins and the use of additional steps as mentioned above results in a product in which more than 70 g, in particular more than 80 g/100 g of dry material is a protein-like material, of which 55-93 g, in particular 65-90 g/100 g of proteins are immunoglobulins.
  • the remainder consists of the components from the complement system, growth factors and other proteins.
  • the immunoglobulins will be of the G-type (IgG). Part thereof, in particular 0.01-5%, are antibodies against preselected toxins or pathogens.
  • the concentration of the components in the final product can be computed by a person skilled in this field by assuming that about 0.001-0.002 g of plasma-protein according to the invention per kilogram of body weight, in particular 0.003-0.014 g/kg of body weight, must be consumed per day in order to be effective. Said amounts are relatively low, because the complement factor from the blood plasma and the immunoglobulins against pathogens, as present in blood plasma, appeared to have a synergetic effect.
  • the concentration of the protein must be about 0.1- 10 g, in particular 0.2-8 g, of plasma proteins per litre.
  • the active component according to the invention is important for the preparation of products to be used as food supplements or as a pharmaceutical product for use with humans and animals, which animals include in particular pigs, cows, poultry, horses and pets such as dogs and cats.
  • the active component exhibits an activity which is favourable in connection with the healing of wounds, the recovery and maintenance of tissue, in particular epithel tissue in the gastrointestinal system, the respiratory system or the skin, the normalisation of the intestinal flora and the prevention or treatment of infections that may occur with wounds and in the gastrointestinal and respiratory systems.
  • Infections in the gastrointestinal system may occur in the intestines, for example in the case of infection-triggered diarrhoea, in the stomach in the case of stomach ulcers and in the throat.
  • An example of an infection in the respiratory system is RSV-infection or Pneumonia.
  • the active component is also capable of influencing the flora in the gastrointestinal system.
  • the growth of specific icro- organisms is impeded, enabling the flora in the intestines to normalise, for example in the case of diarrhoea or bacterial overgrowth.
  • the integrity of the tissue in the gastrointestinal system is in particular important in order to obtain a sufficiently great barrier function.. During and after surgery and during illnesses in which the immune function has been affected it is of major importance to prevent infections and sepsis.
  • wounds constitutes another aspect of the invention.
  • Said wounds may occur on the skin, for example after traumatic experiences such as fire, cuts or infections and in the case of eczema, but also on deeper surfaces, for example after decubitus, surgery or radiotherapy.
  • the pharmaceutical preparation may also be used to prevent infections as referred to above.
  • the application determines the form of the product according to the invention.
  • the treatment of the skin is preferably carried out by local application. This can take place by using a gel, an emulsion, an ointment or other forms known to those skilled in this field.
  • the treatment of the respiratory system can take place by administering the pharmaceutical product in the form of a spray or an aerosol, for example.
  • the treatment of the gastrointestinal system can take place by enteral administration of the products.
  • Formulations in liquid form as well as formulations in dry form are suitable. Examples of relatively dry formulations are tablets, capsules, suppositories and the like.
  • the products may have a low dry matter content, for example lower than 50% and in particular lower than 20%. Emulsions, gels and mixtures are the most suitable forms in that case.
  • Example 1 The blood of pigs was hyperimmunised by means of an extract from the faeces of children who suffered from diarrhoea. The blood was further treated by removing fibrin and albumin therefrom, followed by filtration and dialysis. Dry matter (100 g) consisted of 93 g of proteins and 7 g of remaining substances such as lipids, with 86 g/100 g of protein consisting of immunoglobulins and 9 g/100 g of proteins consisting of components belonging to the complement system.
  • a liquid intended for being drip-fed to patients in a hospital was prepared as follows.
  • a composition of 100 ml having an energy value of 420 kJoule contained the following components:
  • Protein 4.0 g viz. 3.9 g of milk proteins (80% casein, 20% whey) and 0.1 g of protein fraction from Example 1.
  • Carbohydrates 12.3 g consisting of 11.1 g of polysaccharides from maltodextrins, 0.7 g of maltose and 0.5 g of remaining substances.
  • a formulation intended for being administered to children contains the following substances per 100 ml, with the energy level being 330 kJ.
  • Protein 2.0 g consisting of 1.9 g of milk proteins and 1.0 g of preparation according to Example 1.
  • Carbohydrates 7.8 g, consisting of 1.6 g of maltodextrins and 6.0 g of lactose, the remainder amounting to 0.2 g.
  • Lipids 4.4 g, consisting of 1.8 g of saturated fatty acids, 0.6 g of milk fat, 1.6 g of mono-unsaturated fatty acids, 0.65 g of polyon-saturated fatty acids and 0.35 g of glycerol as triglyceride.
  • composition according to Example 4 can be used for reducing the significant occurrence of diarrhoea (possible reduction of the dry solid matter content) and significantly reducing the concentration of pathogens in faeces.
  • a soft cream consisting of the following constituents:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un produit pharmaceutique ou un complément alimentaire, qui contient comme élément actif une préparation obtenue à partir du plasma sanguin, et dans lequel la préparation contient une plus grande quantité de système du complément (CS) et/ou d'anticorps (immunoglobuline) qu'on en compte normalement. L'invention concerne en outre un produit pharmaceutique présenté sous une forme appropriée pour une application médicale, et le complément alimentaire présenté sous une forme solide ou liquide; ainsi que le produit intermédiaire à utiliser.
PCT/NL2002/000640 2001-10-08 2002-10-07 Produit pharmaceutique ou complement alimentaire, et produit intermediaire a utiliser avec ces produits WO2003030918A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1019143A NL1019143C2 (nl) 2001-10-08 2001-10-08 Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct.
NL1019143 2001-10-08

Publications (1)

Publication Number Publication Date
WO2003030918A1 true WO2003030918A1 (fr) 2003-04-17

Family

ID=19774152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2002/000640 WO2003030918A1 (fr) 2001-10-08 2002-10-07 Produit pharmaceutique ou complement alimentaire, et produit intermediaire a utiliser avec ces produits

Country Status (2)

Country Link
NL (1) NL1019143C2 (fr)
WO (1) WO2003030918A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8407912B2 (en) 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
WO2013092861A1 (fr) 2011-12-23 2013-06-27 Veos N.V. Composition enrichie en glycoprotéine en tant qu'additif d'aliment pour humains et/ou animaux et/ou en tant qu'agent thérapeutique
US8533972B2 (en) 2010-10-29 2013-09-17 Velico Medical, Inc. System and method for spray drying a liquid
WO2015095650A1 (fr) 2013-12-19 2015-06-25 Puretein Bioscience Llc. Méthodes de traitement d'un animal
US9867782B2 (en) 2009-04-09 2018-01-16 Entegrion, Inc. Spray-dried blood products and methods of making same
US10251911B2 (en) 2009-09-16 2019-04-09 Entegrion, Inc. Spray dried human plasma
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB652641A (en) * 1947-06-03 1951-04-25 Wisconsin Alumni Res Found Process of preparing antibody-rich globulin fractions
GB715101A (en) * 1952-04-18 1954-09-08 Wisconsin Alumni Res Found A veterinary prophylactic composition for the treatment of scours
GB1297011A (fr) * 1969-01-17 1972-11-22
US4965068A (en) * 1985-05-04 1990-10-23 Biotest Pharma Gmbh Polyvalent hyperimmunoglobulin preparation
WO1996010420A1 (fr) * 1994-10-04 1996-04-11 Sotomayor, Tevic, Emar Composition et traitement d'hyperimmunisation a l'aide de bacteries non tuees thermiquement
RU2158136C1 (ru) * 1999-06-15 2000-10-27 Кировский НИИ гематологии и переливания крови Способ получения igm-содержащего концентрата иммуноглобулина

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB652641A (en) * 1947-06-03 1951-04-25 Wisconsin Alumni Res Found Process of preparing antibody-rich globulin fractions
GB715101A (en) * 1952-04-18 1954-09-08 Wisconsin Alumni Res Found A veterinary prophylactic composition for the treatment of scours
GB1297011A (fr) * 1969-01-17 1972-11-22
US4965068A (en) * 1985-05-04 1990-10-23 Biotest Pharma Gmbh Polyvalent hyperimmunoglobulin preparation
WO1996010420A1 (fr) * 1994-10-04 1996-04-11 Sotomayor, Tevic, Emar Composition et traitement d'hyperimmunisation a l'aide de bacteries non tuees thermiquement
RU2158136C1 (ru) * 1999-06-15 2000-10-27 Кировский НИИ гематологии и переливания крови Способ получения igm-содержащего концентрата иммуноглобулина

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200114, Derwent World Patents Index; Class B04, AN 2001-135434, XP002200079 *
F. EMMRICH ET AL: "Quantative alterations of immune serum globulin concentrations", EXPERIMENTELLE PATHOLOGIE, vol. 14, no. 6, 1977, pages 334 - 339, XP002200078 *
M. SUTER ET AL: "Stimulation of Immunoglobulin-Containing Cells and Isotype-Specific Antibody Response in Experimental Mycoplasma hyponeumoniae Infection in Specific-Pathogen-Free Pigs", INFECTION AND IMMUNITY, vol. 49, no. 3, 1985, pages 615 - 620, XP001059157 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867782B2 (en) 2009-04-09 2018-01-16 Entegrion, Inc. Spray-dried blood products and methods of making same
US11213488B2 (en) 2009-04-09 2022-01-04 Entegrion, Inc. Spray-dried blood products and methods of making same
US10251911B2 (en) 2009-09-16 2019-04-09 Entegrion, Inc. Spray dried human plasma
US8434242B2 (en) 2010-09-16 2013-05-07 Velico Medical, Inc. Spray dried human plasma
US8407912B2 (en) 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
US8533972B2 (en) 2010-10-29 2013-09-17 Velico Medical, Inc. System and method for spray drying a liquid
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US8595950B2 (en) 2010-10-29 2013-12-03 Velico Medical, Inc. System and method for spray drying a liquid
CN104144612A (zh) * 2011-12-23 2014-11-12 富得派有限责任公司 作为食物和/或饲料添加剂和/或作为治疗剂的糖蛋白富集的组合物
WO2013092861A1 (fr) 2011-12-23 2013-06-27 Veos N.V. Composition enrichie en glycoprotéine en tant qu'additif d'aliment pour humains et/ou animaux et/ou en tant qu'agent thérapeutique
BE1020455A3 (nl) * 2011-12-23 2013-10-01 Veos Nv In glycoproteine verrijkte samenstelling als voedings- en/of diervoederadditief en/of als therapeutisch middel.
WO2015095650A1 (fr) 2013-12-19 2015-06-25 Puretein Bioscience Llc. Méthodes de traitement d'un animal
US10279013B2 (en) 2013-12-19 2019-05-07 Puretein Bioscience Llc Methods for treating an animal
EP3082841A4 (fr) * 2013-12-19 2017-07-26 Puretein Bioscience, LLC Méthodes de traitement d'un animal
US11806431B2 (en) 2014-09-19 2023-11-07 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US12064518B2 (en) 2014-09-19 2024-08-20 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11913723B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Baffle plate used in a disposable for a spray drying system
US11913722B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Rapid spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US12092397B2 (en) 2022-09-15 2024-09-17 Velico Medical, Inc. Disposable for a spray drying system

Also Published As

Publication number Publication date
NL1019143C2 (nl) 2003-04-09

Similar Documents

Publication Publication Date Title
Yalcin Emerging therapeutic potential of whey proteins and peptides
Korhonen et al. Milk immunoglobulins and complement factors
US20040047856A1 (en) Colorstrum-based composition
DE68924142T2 (de) Biologisch aktive Molkeproteinzusammenzetzung, Verfahren zur Herstellung und Verwendung dieser Zusammensetzung.
AU771583B2 (en) Bone resorption suppressing agent
Korhonen Production and properties of health-promoting proteins and peptides from bovine colostrum and milk
KR100297959B1 (ko) 유장단백질로hiv-혈청양성개체의치료방법
CA2077482C (fr) Produits hypoallergenes faits de composants naturels ou synthetiques, et procede de fabrication
JP3195631B2 (ja) 特異的鶏卵抗体の製造方法
US5645834A (en) Method and product for treating failure of passive transfer and improving milk production in bovine species
WO2003030918A1 (fr) Produit pharmaceutique ou complement alimentaire, et produit intermediaire a utiliser avec ces produits
US6096310A (en) Oral immunotherapy of bacterial overgrowth
KR20100108557A (ko) 간기능 보호제
CA2349980C (fr) Methode de production de fractions contenant une forte concentration de cystatine, une proteine de base du lait, et produits de decomposition connexes
KR101433648B1 (ko) 피부미용제
TWI620506B (zh) 發酵乳類之用途及其製造方法
WO1999002188A1 (fr) Anticorps de jaune d'oeuf de poule, diriges contre les antigenes de clostridium difficile et leur utilisation dans le traitement de la colite pseudomembraneuse
AU784087B2 (en) Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
TWI620509B (zh) 飲料之用途及其製造方法
Sydney et al. Colostrum new insights: products and processes
JP3693377B2 (ja) 生体内で感染防御作用を有するペプチド混合物と、このペプチド混合物を含有する組成物
JP6562956B2 (ja) 飲料及びその製造方法
Galali et al. Journal of Family Medicine and Disease Prevention
TWI620508B (zh) 飲料及其製造方法
Kumar et al. Nutritional importance of colostrum in different farm animals-A Critical

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP